Global Blood Therapeutics, Inc.
GBT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $195 | $124 | $2 | $0 |
| % Growth | 57.3% | 5,773% | – | – |
| Cost of Goods Sold | $3 | $2 | $0 | $0 |
| Gross Profit | $191 | $122 | $2 | $0 |
| % Margin | 98.3% | 98.4% | 97.7% | – |
| R&D Expenses | $212 | $155 | $175 | $131 |
| G&A Expenses | $0 | $0 | $117 | $51 |
| SG&A Expenses | $267 | $211 | $117 | $51 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $479 | $366 | $292 | $183 |
| Operating Income | -$287 | -$243 | -$281 | -$183 |
| % Margin | -147.4% | -196.4% | -13,343.6% | – |
| Other Income/Exp. Net | -$15 | -$4 | $15 | $9 |
| Pre-Tax Income | -$303 | -$248 | -$267 | -$174 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$303 | -$248 | -$267 | -$174 |
| % Margin | -155.6% | -200% | -12,654.9% | – |
| EPS | -4.82 | -4.04 | -4.57 | -3.41 |
| % Growth | -19.3% | 11.6% | -34% | – |
| EPS Diluted | -4.82 | -4.04 | -4.57 | -3.41 |
| Weighted Avg Shares Out | 63 | 61 | 58 | 51 |
| Weighted Avg Shares Out Dil | 63 | 61 | 58 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $6 | $0 | $0 |
| Interest Expense | $15 | $10 | $0 | $0 |
| Depreciation & Amortization | $9 | $11 | $10 | $5 |
| EBITDA | -$279 | -$227 | -$257 | -$170 |
| % Margin | -143% | -183.3% | -12,183.8% | – |